Michael J. Fox Foundation

The study will provide researchers, drugmakers, regulators, and payors with insight into the genetics of the disease and experience of the patients.

Using data from the Parkinson's Progression Markers Initiative, GNS Healthcare identifies genetic and molecular markers of rapid motor progression.

The study will screen patients using a combination of genotyping and wireless sensors to develop a better diagnostic method. 

NEW YORK (GenomeWeb) – The Michael J. Fox Foundation for Parkinson's Research has awarded Sok Kean Khoo, an associate professor of molecular genomics at Grand Valley State University, a $110,000 grant to study molecular biomarkers for monitoring the advancement of Parkinson's disease.

NEW YORK (GenomeWeb News) – KineMed today reported the Michael J. Fox Foundation has awarded it an additional $1.2 million to continue development of kinetic biomarkers for Parkinson's disease.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Lucigen today announced it has received a $187,000 grant from the Michael J. Fox Foundation to study a protein that has been implicated in Parkinson's disease.

A 23andMe and Parkinson's Institute team has tracked down two new risk loci for Parkinson's disease and verified many more through a web-based genome-wide association study involving more than 3,400 cases and nearly 30,000 controls.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

The foundation will be working with collaborators to develop assays based on two protein candidate biomarkers.

SAGE labs will use Michael J. Fox Foundation funding to develop rat models for research.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.